D W Fry - JoVE Visualize

Showing results (41-50 of 82) with videos related to

Pageof 9

Sort By:

Peptides|January 1, 1994

Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-gamma 1D W Fry, A McMichael, J Singh, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent mannerM Bos, J Mendelsohn, Y M Kim, et al.

Cancer Research|March 1, 1985

Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitroL H Matherly, M K Voss, L A Anderson, et al.

Molecular Pharmacology|August 1, 1993

Inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase by the monophosphate metabolite of 4-amino-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine: a novel mechanism for antitumor activityD W Fry, T J Boritzki, R C Jackson, et al.

Journal of Medicinal Chemistry|March 28, 1997

Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinasesJ Singh, E M Dobrusin, D W Fry, et al.

Clinical and Experimental Pharmacology & Physiology|May 1, 1996

Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitroW A Denny, G W Rewcastle, A J Bridges, et al.

Biochemical Pharmacology|November 1, 1988

Inhibition of type II topoisomerase by fostriecinT J Boritzki, T S Wolfard, J A Besserer, et al.

Anticancer Research|June 16, 1999

Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitorsY Sun, D W Fry, P Vincent, et al.

Journal of Medicinal Chemistry|September 15, 1995

Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, A J Bridges, D W Fry, et al.

Journal of Medicinal Chemistry|June 6, 1997

Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptorG W Rewcastle, A J Bridges, D W Fry, et al.

Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:

Pageof 9

Peptides|January 1, 1994

Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-gamma 1D W Fry, A McMichael, J Singh, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent mannerM Bos, J Mendelsohn, Y M Kim, et al.

Cancer Research|March 1, 1985

Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitroL H Matherly, M K Voss, L A Anderson, et al.

Molecular Pharmacology|August 1, 1993

Inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase by the monophosphate metabolite of 4-amino-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine: a novel mechanism for antitumor activityD W Fry, T J Boritzki, R C Jackson, et al.

Journal of Medicinal Chemistry|March 28, 1997

Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinasesJ Singh, E M Dobrusin, D W Fry, et al.

Clinical and Experimental Pharmacology & Physiology|May 1, 1996

Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitroW A Denny, G W Rewcastle, A J Bridges, et al.

Biochemical Pharmacology|November 1, 1988

Inhibition of type II topoisomerase by fostriecinT J Boritzki, T S Wolfard, J A Besserer, et al.

Anticancer Research|June 16, 1999

Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitorsY Sun, D W Fry, P Vincent, et al.

Journal of Medicinal Chemistry|September 15, 1995

Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, A J Bridges, D W Fry, et al.

Journal of Medicinal Chemistry|June 6, 1997

Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptorG W Rewcastle, A J Bridges, D W Fry, et al.

Pageof 9